Skip to content
Screener

Biogen BIIB Shares (Diluted)

Shares (Diluted) at other companies

Eli Lilly logo
Eli LillyLLY
895.9M-0.5%
Rogers Corporation logo
Rogers CorporationROG
18M-2.2%
TG Therapeutics logo
TG TherapeuticsTGTX
160.1M-1.7%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
172.7M+3.0%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
28.7M-6.4%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
88.3M+2.4%

Other financials

Income statement

See full
Revenue$2.7B+3.4%
Gross profit$2.0B-4.0%
Operating income$610.7M
Net income$97.5M-84.6%
EPS (diluted)$0.66-84.8%

Balance sheet

See full
Cash & equivalents$1.3B-53.4%
Total debt$7.6B+14.6%
Total equity$18.8B+6.9%
Total assets$32.1B+13.3%

Cash flow

See full
Operating cash flow$448.9M+179%
CapEx$40.9M+53.8%
Free cash flow$408.0M+204%

Valuation

See full
Market cap$29.99B+54.7%
Enterprise value$36.26B+56.2%
P/E33.9×+21.3×
P/S+1.1×

Profitability

See full
Gross margin74%-1.4pp
Operating margin22.9%
Net margin8.8%-6.5pp
FCF margin26.9%+7.1pp

Returns & leverage

See full
Return on equity4.8%-4.3pp
Debt / equity0.4×0.0×
Current ratio1.9×-0.6×

Where this comes from

Reported directly by Biogen in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Biogen’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 6:36 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000875045-26-000075
Line itemFor the Three Months Ended June 30, 2026For the Three Months Ended June 30, 2025For the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
Income tax (benefit) expense34.9109.293.1179.9
Net income attributable to Biogen Inc.$97.5$634.8$417.0$875.3
Net income per share:
Basic earnings per share attributable to Biogen Inc.$0.66$4.33$2.83$5.98
Diluted earnings per share attributable to Biogen Inc.$0.66$4.33$2.81$5.97
Weighted-average shares used in calculating:
Basic earnings per share attributable to Biogen Inc.147.7146.5147.4146.3
Diluted earnings per share attributable to Biogen Inc.148.7146.7148.6146.7

Item 1. Financial Statements (unaudited)

FAQ

What is Biogen's shares (diluted)?
Biogen (BIIB) reported shares (diluted) of 148.7M in Q2 2026.
How has Biogen's shares (diluted) changed year-over-year?
Biogen's shares (diluted) increased by 1.4% year-over-year, from 146.7M to 148.7M.
What is the long-term trend for Biogen's shares (diluted)?
Over 4 years (2021 to 2025), Biogen's shares (diluted) has grown at a -0.5% compound annual growth rate (CAGR), from 600.6M to 587.5M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Biogen's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude